metformin has been researched along with Autoimmune Diseases in 14 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on metformin and other anti-diabetic agent prescriptions, we categorized all patients with autoimmune diseases into either the metformin group (metformin administration for at least 28 days) or the non-metformin group." | 8.02 | Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases. ( Chen, TH; Hsu, CY; Lin, CY; Lin, MS; Lin, YS; Su, YJ; Wu, CH, 2021) |
| "Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently." | 6.94 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. ( Ajjan, R; Ajodha, S; Akanle, O; Bestwick, JP; Christ-Crain, M; Fraser, W; Gabrovska, P; Grossman, AB; Kelly, S; Kola, B; Korbonits, M; Pernicova, I; Pitzalis, C; Sahdev, A; Stadler, M, 2020) |
| "Autoimmune diseases are characterized by the production of autoantibodies directed against specific organs of own organism." | 6.53 | Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug. ( Bijak, M; Saluk, J; Tomczynska, M, 2016) |
| "A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high." | 6.53 | Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. ( Cao, X; Feng, X; Hu, Y; Jiang, L; Li, Q; Liu, C; Luo, Y; Ma, J; Wang, Y; Yan, R; Yang, F; Yuan, L; Zhao, E; Zhu, Y, 2016) |
| "Metformin was discontinued on day 22 (16 days after reintroduction) and neutropenia promptly reversed during next week with 1." | 5.35 | Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma. ( Hamdi, S; Huguet, F; Laporte, F; Oksman, F, 2008) |
| "Metformin treatment for one year improved HbA1c in both groups (with and without type-1 LADA)." | 5.34 | [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]. ( Arroyo Bros, J; Campos Bonilla, B; Granada Ybern, ML; Lóriz Peralta, O; Sanmartí Sala, A, 2007) |
| " Based on metformin and other anti-diabetic agent prescriptions, we categorized all patients with autoimmune diseases into either the metformin group (metformin administration for at least 28 days) or the non-metformin group." | 4.02 | Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases. ( Chen, TH; Hsu, CY; Lin, CY; Lin, MS; Lin, YS; Su, YJ; Wu, CH, 2021) |
| "Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently." | 2.94 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. ( Ajjan, R; Ajodha, S; Akanle, O; Bestwick, JP; Christ-Crain, M; Fraser, W; Gabrovska, P; Grossman, AB; Kelly, S; Kola, B; Korbonits, M; Pernicova, I; Pitzalis, C; Sahdev, A; Stadler, M, 2020) |
| "A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high." | 2.53 | Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. ( Cao, X; Feng, X; Hu, Y; Jiang, L; Li, Q; Liu, C; Luo, Y; Ma, J; Wang, Y; Yan, R; Yang, F; Yuan, L; Zhao, E; Zhu, Y, 2016) |
| "Metformin was discontinued on day 22 (16 days after reintroduction) and neutropenia promptly reversed during next week with 1." | 1.35 | Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma. ( Hamdi, S; Huguet, F; Laporte, F; Oksman, F, 2008) |
| "Metformin treatment for one year improved HbA1c in both groups (with and without type-1 LADA)." | 1.34 | [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]. ( Arroyo Bros, J; Campos Bonilla, B; Granada Ybern, ML; Lóriz Peralta, O; Sanmartí Sala, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HJ | 1 |
| Jeong, IK | 1 |
| Hur, KY | 1 |
| Kim, SK | 1 |
| Noh, JH | 1 |
| Chun, SW | 1 |
| Kang, ES | 1 |
| Rhee, EJ | 1 |
| Choi, SH | 1 |
| Liu, X | 1 |
| Yu, P | 1 |
| Xu, Y | 1 |
| Wang, Y | 2 |
| Chen, J | 1 |
| Tang, F | 1 |
| Hu, Z | 1 |
| Zhou, J | 1 |
| Liu, L | 1 |
| Qiu, W | 1 |
| Ye, Y | 1 |
| Jia, Y | 1 |
| Yao, W | 1 |
| Long, J | 1 |
| Zeng, Z | 1 |
| Pernicova, I | 1 |
| Kelly, S | 1 |
| Ajodha, S | 1 |
| Sahdev, A | 1 |
| Bestwick, JP | 1 |
| Gabrovska, P | 1 |
| Akanle, O | 1 |
| Ajjan, R | 1 |
| Kola, B | 1 |
| Stadler, M | 1 |
| Fraser, W | 1 |
| Christ-Crain, M | 1 |
| Grossman, AB | 1 |
| Pitzalis, C | 1 |
| Korbonits, M | 1 |
| Pålsson-McDermott, EM | 1 |
| O'Neill, LAJ | 1 |
| Lin, CY | 1 |
| Wu, CH | 1 |
| Hsu, CY | 1 |
| Chen, TH | 1 |
| Lin, MS | 1 |
| Lin, YS | 1 |
| Su, YJ | 1 |
| Byun, S | 1 |
| Lee, E | 1 |
| Lee, KW | 1 |
| Ursini, F | 1 |
| Russo, E | 1 |
| Pellino, G | 1 |
| D'Angelo, S | 1 |
| Chiaravalloti, A | 1 |
| De Sarro, G | 1 |
| Manfredini, R | 1 |
| De Giorgio, R | 1 |
| Kim, SC | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Doherty, M | 1 |
| Goldfine, AB | 1 |
| Solomon, DH | 1 |
| Tomczynska, M | 1 |
| Bijak, M | 1 |
| Saluk, J | 1 |
| Feng, X | 1 |
| Yuan, L | 1 |
| Hu, Y | 1 |
| Zhu, Y | 1 |
| Yang, F | 1 |
| Jiang, L | 1 |
| Yan, R | 1 |
| Luo, Y | 1 |
| Zhao, E | 1 |
| Liu, C | 1 |
| Li, Q | 2 |
| Cao, X | 1 |
| Ma, J | 1 |
| Brophy, S | 1 |
| Davies, H | 1 |
| Mannan, S | 1 |
| Brunt, H | 1 |
| Williams, R | 1 |
| Ringel, J | 1 |
| Lerch, MM | 1 |
| Mayerle, J | 1 |
| Lóriz Peralta, O | 1 |
| Campos Bonilla, B | 1 |
| Granada Ybern, ML | 1 |
| Sanmartí Sala, A | 1 |
| Arroyo Bros, J | 1 |
| Laporte, F | 1 |
| Hamdi, S | 1 |
| Oksman, F | 1 |
| Huguet, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study[NCT01319994] | Phase 2/Phase 3 | 57 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Metformin as a Novel Treatment for Vitiligo by Targeting CD8+ T Cell Metabolism[NCT05607316] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
change in visceral/subcutaneous fat (NCT01319994)
Timeframe: 3 months minus baseline
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 0.08 |
| Placebo | -0.03 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). HOMA2-IR is calculated using the HOMA model: www.dtu.ox.ac.uk/homacalculator/ (NCT01319994)
Timeframe: 3 months minus baseline
| Intervention | HOMA score (Mean) |
|---|---|
| Metformin | 0.22 |
| Placebo | 2.35 |
7 reviews available for metformin and Autoimmune Diseases
| Article | Year |
|---|---|
Targeting immunometabolism as an anti-inflammatory strategy.
Topics: Anti-Inflammatory Agents; Autoimmune Diseases; Dimethyl Fumarate; Glycolysis; Humans; Immunomodulati | 2020 |
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Hu | 2017 |
Metformin and Autoimmunity: A "New Deal" of an Old Drug.
Topics: Animals; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Fibroblasts; Gastrointestinal Microbiome; | 2018 |
Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Autoimmune Diseases; Clinical Trials as Topic | 2016 |
Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature.
Topics: Acarbose; Aged; Autoimmune Diseases; Diabetes Mellitus, Type 2; Drug Substitution; Gliclazide; Human | 2016 |
Interventions for latent autoimmune diabetes (LADA) in adults.
Topics: Adult; Autoimmune Diseases; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glutamate Decarboxylas | 2011 |
[Pancreatic diseases: update 2011].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Diabetes Mellitus; Diagnosis, D | 2011 |
2 trials available for metformin and Autoimmune Diseases
| Article | Year |
|---|---|
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, T | 2022 |
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
Topics: Adult; Aged; Autoimmune Diseases; Double-Blind Method; Female; Glucocorticoids; Humans; Hypoglycemic | 2020 |
5 other studies available for metformin and Autoimmune Diseases
| Article | Year |
|---|---|
Metformin induces tolerogenicity of dendritic cells by promoting metabolic reprogramming.
Topics: Autoimmune Diseases; Citric Acid Cycle; Dendritic Cells; Fatty Acids; Humans; Lipid Metabolism; Metf | 2023 |
Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Cell Proliferation; Databases, Factual; Diabete | 2021 |
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2015 |
[Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?].
Topics: Adult; Aged; Autoantibodies; Autoimmune Diseases; Body Mass Index; Confidence Intervals; Diabetes Me | 2007 |
Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Granulocytes; Humans; Hypoglycemic Agents; Leukocy | 2008 |